期刊文献+

按AUC与体表面积计算伯尔定用量化疗毒性和疗效比较 被引量:3

下载PDF
导出
摘要 【目的】为比较按药物血浆浓度 时间曲线下面积 (AUC)与体表面积计算伯尔定用量的两种方法在化疗中对血液毒性和疗效的影响。【方法】按接收的先后顺序 ,42例病人单盲随机分为按体表面积计算组和按AUC计算两组 ,总结两组的血液性毒性和疗效 ,并进行了对比研究。【结果】 42例病人均可评价疗效 ,AUC和体表面积两组有效率分别为 47 6 1%和 19 0 5 %。AUC组明显高于体表面积组 ,但P =0 0 5 ;AUC组和体表面积组白细胞 (WBC)减少发生率分别为 38 10 %和 76 2 0 % ,Ⅲ和Ⅳ度为 4 76 %和 2 8 5 7% (P >0 0 5 ) ;血小板 (Pt)减少发生率分别为 4 76 %和 19 0 5 % (P >0 0 5 ) ;血红蛋白 (Hb)减少发生率均为 47 6 2 % ,Ⅲ和Ⅳ度为 9 5 2 %和 4 76 % (P >0 0 5 )。【结论】应用伯尔定行全身化疗 ,按AUC计算用药剂量在提高疗效和降低血液毒性反应方面优于按体表面积计算。
出处 《中山医科大学学报》 CSCD 北大核心 2002年第B09期93-94,共2页 Academic Journal of Sun Yat-sen University of Medical Sciences
  • 相关文献

参考文献8

  • 1周际昌.实用肿瘤外科学[M].北京:人民卫生出版社,1999.333-338.
  • 2储大同,罗扬,李峻岭,郝学志,张湘茹,李雅玲.卡铂按AUC给药对小细胞肺癌疗效和毒性的影响[J].中国肿瘤临床,2001,28(1):28-30. 被引量:13
  • 3Newell D R, Siddik Z H, Gumbrell L A, et al. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin[J]. Eur J Cancer Clin Oncol, 1987,23(9) : 1399.
  • 4Collins J M, Zaharko D S, Dedriek R L, et al. Potential roles for preclinical pharmacology in phase Ⅰ clinical trials[J] .Cancer Treat Rep, 1986,70( 1 ) : 73.
  • 5Calvert A H, Newell D R. Gumbrell L A, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function[J] .Clinic Oncol, 1989,7( 11 ) : 1748.
  • 6Okamoto H, Nagatomo A, Kunitoh H, et al. prediction of carboplatin in clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of the performance of three formulae [ J ] . Cancer Chemother Pharmacol, 1998, 42(4) : 307.
  • 7Langer C J, Leighton J C, Comis R L, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase Ⅱ toxicity, response, and survival analysis[J]. J Clin Oncol, 1995,13(8): 1860.
  • 8Egorin M J, Van Echo D A, Olman E A, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloro-platinum ( Ⅱ ) analogue diamminecy- clobutanedicarboxylato platinum [ J ]. Cancer Res, 1985,45 ( 12 pt 1 ) : 6502.

二级参考文献1

共引文献12

同被引文献26

  • 1林美英,宋昱晨,时国朝.据AUC计算卡铂的剂量[J].中国医学文摘(内科学),2004(5):686-688. 被引量:1
  • 2刘秋菊,姜玉珍,贾姣源.化疗后骨髓抑制危险因素分析[J].江西医学院学报,2005,45(3):48-50. 被引量:20
  • 3Sculier JP, Paesmans M, Thiriaux J, et al. A comparison of methods of calculation for estimating earboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer. 1999.35 : 1314-1319.
  • 4Dees EC, Watkins PB. Role of cytochrome P450 phenotyping in cancer treatment. J Clin Oncol,2005 ,23 :1053-1055.
  • 5Jodrell DI, Egorin M J, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol, 1992,10:520-528.
  • 6Alvarez RD, Armstrong DK, Chen LM, et al. Ovarian Cancer. NCCN Clinical Practice Guidelines in Oncology[ EB/OL]. (2008- 03-30) [ 2011-03-03 ]. http://www, nccn. org/professionals/ physician_gls/pdf/ovarian, pdf.
  • 7Okamoto H, Nagatomo A, Kunitoh H, et al. Prediction of carboplatin clearance calculated by patient characteristics or 24- hour creatinine clearance : a comparison of the performance of three formulae. Cancer Chemother Pharmacol,1998 ,42 :307-312.
  • 8Calvert AH, Newel1 DR, Gumbre11 LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol, 1989,7 : 1748-1756.
  • 9McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ill and stage IV ovarian cancer. N Engl J Med, 1996, 334:1-6.
  • 10Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer,2004,100:228-237.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部